[1]席俊峰a,彭彦才a,马兴聪,等.Aurora-B 激酶的表达与非小细胞肺癌患者预后及耐药的相关性分析[J].现代检验医学杂志,2020,35(06):59-63.[doi:doi:10.3969/j.issn.1671-7414.2020.06.015]
　XI Jun-feng a,PENG Yan-cai a,MA Xing-cong,et al.Study on the Relationship between High Expression of Aurora-B Kinase andDrug Resistance and Prognosis in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):59-63.[doi:doi:10.3969/j.issn.1671-7414.2020.06.015]
点击复制

Aurora-B 激酶的表达与非小细胞肺癌患者预后及耐药的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年06期
页码:
59-63
栏目:
论著
出版日期:
2020-12-30

文章信息/Info

Title:
Study on the Relationship between High Expression of Aurora-B Kinase andDrug Resistance and Prognosis in Patients with Non-Small Cell Lung Cancer
文章编号:
1671-7414（2020）06-059-05
作者:
席俊峰1a ; 彭彦才1a ; 马兴聪2 ; 郝光军1b
（1. 榆林市第一医院 a. 胸心外科；b 肿瘤科；陕西榆林 719000；2. 西安交通大学第二附属医院肿瘤病院 , 西安 710004）
Author(s):
XI Jun-feng 1a ;  PENG Yan-cai 1a ;  MA Xing-cong 2 ;  HAO Guang-jun 1b
（1a. Cardio-Thoracic Surgery; 1b. Department of Oncology, the First Hospital of Yulin City, Shaanxi Yulin 719000,China；2.Oncology Hospital,the Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an710004,China）
关键词:
非小细胞肺癌; Aurora-B 激酶; 预后; 耐药性
分类号:
R734.2；R730.43
DOI:
doi:10.3969/j.issn.1671-7414.2020.06.015
文献标志码:
A
摘要:
目的　检测非小细胞肺癌（NSCLC）患者病理组织中 Aurora-B 激酶的表达情况，并探讨其对患者预后的影响及与肿瘤耐药的相关性。方法　收集 194 例非小细胞肺癌患者肿瘤组织标本 , 应用免疫组织化学方法检测 Aurora-B 激酶的表达情况。以 Log-Rank 检验比较 Aurora-B 激酶表达阳性患者与阴性患者总生存时间的差异，采用 COX 模型探索非小细胞肺癌患者预后的影响因素；分离患者肿瘤细胞进行耐药性诱导实验，并通过测量 IC50 的变化初步评价细胞耐药情况。结果　非小细胞肺癌组织中 Aurora-B 激酶表达阳性率为 63.92%（124/194）。Aurora-B 激酶阳性患者的总生存时间低于 Aurora-B 激酶阴性患者（P<0.000 1）；COX 模型显示 Aurora-B 激酶表达（HR=4.03，95%CI：1.80~9.01, P=0.000 7）、肿瘤病理类型（HR=2.11，95%CI：1.17~3.79, P=0.035 7）及临床分期（HR=0.42，95%CI：0.24~0.74, P=0.002 7）是影响患者总生存时间的因素；经过耐药性诱导，Aurora-B 激酶阳性肿瘤细胞 IC50 显著增加，且增幅高于 Aurora-B 激酶阴性肿瘤细胞，其差异有统计学意义（P<0.000 1）。结论　Aurora-B 激酶在非小细胞肺癌中表达异常增高，与患者预后呈负相关，并与非小细胞肺癌耐药性相关，提示 Aurora-B 激酶可能成为非小细胞肺癌预后的标志物及潜在治疗靶点。

参考文献/References:

[1] 陈万青，郑荣寿，曾红梅，等 .2011 年中国恶性肿瘤发病和死亡分析 [J]. 中国肿瘤 , 2015, 24（1）:1-10.CHEN Wanqing, ZHENG Rongshou, ZENG Hongmei,et al. Report of cancerincidence and mortality in China,2011 [J]. China Cancer, 2015, 24(1): 1-10.
[2] 张慧颖 , 高全立 . 非小细胞肺癌免疫治疗研究进展[J]. 国际免疫学杂志，2014,37(3):218-222.ZHANG Huiying, GAO Quanli. The research pro-gression of immunotherapy for non-small-cell lungcancer [J]. International Journal of Immunolo-gy,2014,37(3):218-222.
[3] 廖晓宁 , 罗彪 , 张倬彬 , 等 . 非小细胞肺癌放射治疗研究进展 [J]. 医药前沿 ,2017,7(6):6-7.LIAO Xiaoning, LUO Biao, ZHANG Zhuobin, et al.Non-small cell lung cancer radiotherapy were reviewed[J].Journal of Frontiers of Medicine,2017,7(6):6-7.
[4] 金静思 , 贺巾钊 , 周黎明 , 等 . 非小细胞肺癌分子靶向治疗药物的现状及进展 [J]. 中国肿瘤临床 ,2015,42(17):881-885.JIN Jingsi, HE Jinzhao, ZHOU Liming, et al. The prog-ress of molecular-targeted therapeutic drugs in non-small cell lung cancer [J]. Chinese Journal of ClinicalOncology,2015,42(17):881-885.
[5] HUMBERTO P?REZ-OLAIS J, RUIZ-JIM?NEZF,CALDER?N-GARCIA E J, et al. The activity ofAurora kinase B is required for dengue virus release[J].Virus Research, 2019, 274: 197777.
[6] ALAFATE W, WANG Maode, ZUO Jie, et al. Targetingaurora kinase B attenuates chemoresistance in glioblas-toma via a synergistic manner with temozolomide[J].Pathology Research and Practice, 2019, 215(11):152617.
[7] DING Lidan, YANG Liu, HE Yuqi, et al. CREPT/RPRDIB associates with aurora B to regulate cyclin B1expression for accelerating the G2/M transition in gas-tric cancer[J]. Cell Death & Disense, 2018, P(12):1172.
[8] CICENAS J. The Aurora kinase inhibitors in cancerresearch and therapy[J]. Journal of Cancer Researchand Clinical Oncology, 2016, 142(9): 1995-2012.
[9] TANG Anqun, GAO Keyu, CHU Laili, et al. Aurorakinases: novel therapy targets in cancers[J]. Oncotarget,2017, 8(14): 23937-23954.
[10] WILLIAMS M M, MATHISON A J, CHRISTENSEN T,et al. Aurora kinase B-phosphorylated HP1α functionsin chromosomal instability.[J]. Cell cycle (Georgetown,Tex.), 2019, 18(12):1-15.
[11] HETLAND T E, NYMOEN D A, HOLTH A, et al.Aurora B expression in metastatic effusions fromadvanced-stage ovarian serous carcinoma is predictiveof intrinsic chemotherapy resistance[J]. HumanPathology, 2013, 44(5): 777-785.
[12] YOON M J, PARK S S, KANG Youjung, et al.Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin[J].Carcinogenesis, 2012, 33(3): 492-500.
[13] GRUNDY M, SEEDHOUSE C, RUSSELL N H, etal. P-glycoprotein and breast cancer resistance proteinin acute myeloid leukaemia cells treated with theAurora-B Kinase Inhibitor barasertib-hQPA[J]. BMCCancer,2011, 11(1): 254.
[14] GULLY C P, VELAZQUEZ-TORRES G, SHIN J H,et al. Aurora B kinase phosphorylates and instigatesdegradation of p53[J]. Proceedings of the NationalAcademy of Sciences of the United States of America,2012, 109(24): 9323-9233.
[15] MATSUMOTO M, NAKAJIMA W, SEIKE M, etal. Cisplatio-induced apoptosis in non-small celllung cancer cells is dependent on Bax-and Bak-induction pathway and synergistically activated byBH3-mimetic ABT-263 in p53 wild-type and mutantcells [J].Biochemical and Biophysical ResearchCommunications, 2016,473(2):490-496.
[16] GUPTA S, SILVEIRA D A, MOMBACH J C M. ATM/miR-34a-5p axis regulates a p21-dependent senescence-apoptosis switch in non-small cell lung concer: aBoolean model of G1/s checkpoint regulation[J] FEBSLetters, 2020, 594(2):227-239.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(06):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(06):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(06):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

更新日期/Last Update: 2020-12-20